Skip to main content

Table 2 Impact of immunohistochemical staining, IHC expressed (+ve) and those that did not express IHC markers (-ve), for Chromogranin A and neuron specific enolase on overall and cause specific survival

From: Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer

 

CgA+ve

CgA-ve

p-value

NSE +ve

NSE -ve

p value

Overall expression (n, %)

30, 36%

54, 64%

0.005

44,48%

40,52%

0.22

Overall survival (n, %)

5, 17%

45, 83%

0.001

24,55%

26,65%

0.32

Cancer specific survival (n, %)

4, 13%

41, 76%

0.004

21,48%

24,60%

0.30

Metastatic disease (n, %)

18, 60%

17, 32%

0.002

19,43%

16,40%

0.24

  1. CgA: Chromogranin A
  2. NSE: Neuron specific enolase